contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


supar-remedy-llc-announces-the-completion-of-the-public-tender-offer-to-the-shareholders-of-virogates

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Virogates er aktiv inden for medicinsk teknologi. I dag udføres forretningsdrift inden for forskning og udvikling af biomarkører og diagnostiske instrumenter til sundhedsindustrien. Produkterne sælges under forskellige mærker og bruges til identifikation, analyse og videre behandling af sygdomme, hovedsageligt hjerte -kar -sygdomme, kræft og neurologiske sygdomme. Virksomheden blev etableret i 2001 og har sit hovedkontor med beliggenhed i Birkerød.

Virogates

Company Announcement no. 20/2025 (November 20, 2025)BIRKERØD, DENMARK - Today, suPAR Remedy, LLC (the "Offeror") announces the completion of the public tender offer, published on 8 October 2025...

<div class="mfn-header mfn-header-denmark">Company Announcement no. 20/2025 (November 20, 2025)</div><div class="mfn-body">BIRKERØD, DENMARK - Today, suPAR Remedy, LLC (the "Offeror") announces the completion of the public tender offer, published on 8 October 2025 and on 10 October 2025 (the "Public Tender Offer") to the shareholders of ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic inflammation at health clinics and hospitals.As outlined in the attached announcement from the Offeror, the Tender Offer was settled and completed as planned.All documents related to the Public Tender Offer are available <a rel="noopener" href="https://www.virogates.com/public-tender-offer-2025-disclaimer/">here</a>.This announcement is also available at ViroGates’ website click <a rel="noopener" href="https://www.virogates.com/announcements/">here</a>.For further information, please contact: ViroGates A/S: CEO, Jakob Knudsen Tel. (+45) 2226 1355, email: <a rel="noopener" href="mailto:jk@virogates.com">jk@virogates.com</a>Certified Advisor: Västra Hamnen Corporate Finance AB Per Lönn Tel. (+46) 40 200 250 | Email: <a rel="noopener" href="mailto:per.lonn@vhcorp.se">per.lonn@vhcorp.se</a>About ViroGates ViroGates A/S is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and in hospitals to improve hospital patient care. ViroGates markets its blood test products under the suPARnostic® brand.The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (ticker “VIRO”) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit <a rel="noopener" href="http://www.virogates.com/">www.virogates.com</a>.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/e2e6e4cb-4f06-49c3-bca0-edd4f9846263/20251120-virogates-settlement-and-completion.pdf" class="mfn-primary">20251120 ViroGates Settlement And Completion</a></div>

suPAR Remedy, LLC announces the Completion of the public tender offer to the shareholders of ViroGates.